Bally’s Corporation (NYSE: BALY) eyes evoke plc (LSE: EVOK): why a William Hill deal would reshape UK gambling
Read More Pharma Industry News Can C4 Therapeutics (CCCC) balance dilution and growth with its $400m shelf plan? C4 Therapeutics files $400M shelf to support oncology trials. Find out what this means for investors and the company’s future strategy. byPallavi MadhirajuNovember 22, 2025